Corcept Therapeutics (CORT) is back in focus after the FDA issued a Complete Response Letter for relacorilant, followed by securities class action filings that question past disclosures around the drug’s approval prospects.

Corcept’s share price has rebounded to US$42.25, with a 30-day share price return of 25.97% and a 90-day gain of 12.67%, even though the 1-year total shareholder return is still down 37.62%.

If this kind of sharp move after regulatory news has your attention, it could be a good moment to see what else is setting up across 34 healthcare AI stocks

With Corcept now trading at US$42.25, showing solid multi year total returns but a 1 year loss of 37.62%, and sitting well below analyst targets, you have to ask: is this a reset buying chance, or is the market already discounting future growth?

Most Popular Narrative: 33.5% Undervalued

Corcept’s most followed narrative pegs fair value at $63.53 against the current $42.25 share price, which implies a sizeable discount that hinges on specific growth and margin assumptions.

Ottima azienda solida finanziariamente senza debiti a lungo e breve termine. Il FcF tende a diminuire nel tempo mentre aumentano i compensi per i vari membri del board che hanno uno skill in the game moderato. Calcolando il DCF , con un approccio un po ottimistico, quindi , valutando la crescita del fcf al 10% per i primi 5 annni e al 7% dal 6 al 10, calcolando un tasso di sconto al 12% e una crescita del 3% annuo (valore in linea con l aumento medio del pil Usa) il mio fair value è di circa 33 euro al quale sottraggo un MoS del 30% , quindi ho impostato l acquisto a 23 euro circa. Anche il P/E di 31 mi da un' indicazione del genere, Quindi attualmente è sopravvalutata.

Want to see why the narrative still lands above today’s price? The story leans on robust revenue growth, healthy profit margins and a confident discount rate baked into the cash flow path.

Result: Fair Value of $63.53 (UNDERVALUED)

However, this story can change quickly if relacorilant faces further regulatory setbacks or if revenue of US$761.4m becomes more concentrated in a single product.

Another View: Earnings Multiple Sends a Different Signal

While the user DCF points to a fair value of $63.53 and an undervalued setup, the earnings multiple paints a tougher picture. Corcept trades on a P/E of 45.4x versus 33.5x for peers, 16.9x for the US Pharmaceuticals industry and a fair ratio of 33.1x. This suggests a valuation premium that could matter if growth or margins disappoint. Does this look like a safety margin or a tightrope to you?

Next Steps

With mixed signals on value and risk, does this story feel compelling or cautious to you? Act while the data is fresh and weigh both sides with the 2 key rewards and 1 important warning sign

Ready for more investment ideas?

If Corcept’s setup has you thinking about where else value and risk might line up differently, now is the time to scan wider before the next move passes you by.

• Spot potential overreactions by scanning 32 elite penny stocks with strong financials that pair small size with stronger financials than you might expect.
• Prioritize quality at a reasonable price using the 64 high quality undervalued stocks to see which companies combine solid fundamentals with a valuation gap.
• Keep risk in check by focusing on the 72 resilient stocks with low risk scores so you are not relying on a single story to carry your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.